Affordable Access

Access to the full text

Precision Management of Advanced Non–Small Cell Lung Cancer

Authors
  • Yang, Ching-Yao
  • Yang, James Chih-Hsin
  • Yang, Pan-Chyr
Type
Published Article
Journal
Annual Review of Medicine
Publisher
Annual Reviews
Publication Date
Jan 27, 2020
Volume
71
Pages
117–136
Identifiers
DOI: 10.1146/annurev-med-051718-013524
Source
Annual Reviews
Keywords
License
Yellow

Abstract

The rapid evolution of treatment for advanced lung cancer is a story of how scientists have struggled to move from nonselective cytotoxic chemotherapy to personalized precision medicine. In this century, extraordinary advances have been made in the management of advanced and metastatic non–small cell lung cancer, especially in the development of small molecules targeting specific tyrosine kinase receptors and immune checkpoint inhibitors. These developments have led to a significant improvement in survival for lung cancer patients with metastatic disease. Now, the core guidelines to treat non–small cell lung cancer are based on the identification of targetable driver mutations and immune checkpoints. Continued investigations of newly identified druggable genetic alterations, explorations of biomarkers of immune checkpoint inhibitors, development of next-generation immunotherapy, and optimization of combination therapy are necessary to provide better treatment outcomes for lung cancer patients in the future.

Report this publication

Statistics

Seen <100 times